In this regard, in the Canadian Multicentre Osteoporosis Study, Cox2 inhibitor use was associated with a higher BMD in postmenopausal women not using estrogen replacement therapy and perhaps, therefore, with a higher cytokine milieu [50]. Here, PTGS2 is linked to osteoporosis.